These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9935256)

  • 1. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
    Onderdonk AB
    Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
    Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
    Alou L; Anta ML; Del Potro MG; Fuentes F; Balcabao IP; Gomez-Lus ML; Prieto J
    Int J Antimicrob Agents; 1999 Jul; 12(2):135-9. PubMed ID: 10418758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
    Thadepalli H; Chuah SK; Reddy U; Hanna N; Clark R; Polzer RJ; Gollapudi S
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1933-6. PubMed ID: 9303387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
    Vincent J; Teng R; Dalvie DK; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers.
    Garcia-Calvo G; Molleja A; Giménez MJ; Parra A; Nieto E; Ponte C; Aguilar L; Soriano F
    Antimicrob Agents Chemother; 2001 Feb; 45(2):608-11. PubMed ID: 11158764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemistry and biological profile of trovafloxacin.
    Brighty KE; Gootz TD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
    Chávez M; García López JL; Coronilla J; Bernal S; Valverde A; Martín Mazuelos E
    Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trovafloxacin.
    Haria M; Lamb HM
    Drugs; 1997 Sep; 54(3):435-45; discussion 446. PubMed ID: 9279505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
    Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
    J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial therapy for surgical prophylaxis and for intra-abdominal and gynecologic infections.
    Weigelt JA; Faro S
    Am J Surg; 1998 Dec; 176(6A Suppl):1S-3S. PubMed ID: 9935248
    [No Abstract]   [Full Text] [Related]  

  • 15. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers.
    van Nispen CH; Hoepelman AI; Rozenberg-Arska M; Verhoef J; Purkins L; Willavize SA
    Am J Surg; 1998 Dec; 176(6A Suppl):27S-31S. PubMed ID: 9935254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
    Williams DJ; Hopkins S
    Am J Surg; 1998 Dec; 176(6A Suppl):74S-79S. PubMed ID: 9935261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trovafloxacin: a new fluoroquinolone.
    Alghasham AA; Nahata MC
    Ann Pharmacother; 1999 Jan; 33(1):48-60. PubMed ID: 9972385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
    Snydman DR; Jacobus NV; McDermott LA; Supran SE
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1710-2. PubMed ID: 10817736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.